| Aug 15 |
Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
|
| Aug 14 |
Insider Sale: Director Monnas Kampouri Sells Shares of AptarGroup Inc (ATR)
|
| Aug 5 |
Chart advisor: Bitcoin: Yesterday, Today, and Tomorrow
|
| Jul 31 |
O-I Glass (OI) Tops Q2 Earnings Estimates, Lowers '24 Outlook
|
| Jul 31 |
AptarGroup, Inc. (NYSE:ATR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
|
| Jul 27 |
AptarGroup Second Quarter 2024 Earnings: Revenues Disappoint
|
| Jul 26 |
AptarGroup (ATR) Earnings Beat Estimates in Q2, Increase Y/Y
|
| Jul 26 |
AptarGroup, Inc. (ATR) Q2 2024 Earnings Call Transcript
|
| Jul 25 |
AptarGroup (ATR) Beats Q2 Earnings Estimates
|
| Jul 25 |
AptarGroup Non-GAAP EPS of $1.37 beats by $0.02, revenue of $910.06M misses by $20.66M
|
